-
Sophie Vallet,
Sylvie Larrat,
Syria Laperche,
Hélène Le Guillou-Guillemette,
Florence Legrand-Abravanel,
Françoise Bouchardeau,
Adeline Pivert,
Cécile Henquell,
Audrey Mirand,
Elisabeth André-Garnier, [......],
Vincent Mackiewicz,
Lina Aguilera,
Sylvain Rosec,
Stéphanie Gouriou,
Nelly Magnat, Françoise Lunel-Fabiani,
Jacques Izopet,
Patrice Morand,
Christopher Payan,
Jean-Michel Pawlotsky
[show abstract]
[hide abstract]
ABSTRACT: Hepatitis C virus (HCV) protease inhibitor resistance-associated substitutions are selected during triple therapy breakthrough. This multicenter quality control study evaluated the expertise in HCV protease inhibitor resistance genotyping of 23 French laboratories. A panel of 12 well-defined blinded samples comprising two wild-type HCV strains, nine transcripts from synthetic NS3 mutant samples or from clinical strains, and one HCV RNA-negative sample was provided to the participating laboratories. The results showed that any laboratory with expertise in sequencing techniques should be able to provide reliable HCV protease inhibitor resistance genotyping. Only 0.7% erroneous results were reported over the amino acid sites studied. The accuracy of substitution identification ranged from 75% to 100%, depending on the laboratory. Incorrect results were mainly related to the methodology used. The results could be improved by changing the primers and modifying the process in order to avoid cross-contaminations. This study underlines the value of quality control programs for viral resistance genotyping, required prior to launching observational collaborative multicenter studies on HCV resistance to direct-acting antiviral agents.
Journal of clinical microbiology 02/2013; · 4.16 Impact Factor
-
Wael Mansour,
F-Zahra Fall Malick,
Ahmad Sidiya,
Elkhalil Ishagh,
Mariama Abdou Chekaraou,
Pascal Veillon,
Alexandra Ducancelle,
Ségolène Brichler,
Frédéric Le Gal,
Baidy Lo,
Emmanuel Gordien, Françoise Lunel-Fabiani
[show abstract]
[hide abstract]
ABSTRACT: No recent data are available on hepatitis B virus (HBV) and hepatitis Delta virus (HDV) prevalence in Mauritania. One thousand twenty pregnant women and 946 patients visiting for routine checkups were screened for HBV and HDV infection. Demographic, epidemiological, ethnic, clinical, and biological data were recorded. HBV and HDV genotypes were determined by sequencing and phylogenetic analyses. In the pregnant women and patients cohorts, respectively, the prevalence of HBsAg (10.7% and 18.3%) and anti-HBcAb (66.3% and 76.5%) indicated high HBV endemicity. In pregnant women, exposure to HBV was significantly associated in multivariate analysis with education level, ethnicity, blood transfusion, and occupation. HDV antibodies (HDVAb) were found in 14.7% of pregnant women. In patients, HBsAg was found less frequently in females than in males. Again in multivariate analysis, exposure to HBV was significantly correlated with gender (males), and HDVAb positivity with age and gender. The HBV DNA viral load was >3 log IU/ml in only 10.1% of pregnant women and in 17.3% of patients. HDV-RNA was detectable in 21 (67.7%) of the 31 patients positive for HDVAb, and in 11 of the 16 pregnant women positive for HDVAb (68.8%). The most frequent HBV genotypes were: HBV/D, 53%; HBV/E, 35%; and HBV/A, 12%. Sub-genotyping revealed HBV/D1,/D7, and the recently described/D8. HDV genotypes were: HDV-1, 90.3% and HDV-5, 9.7%. This study confirms the high prevalence of HBV and HDV infections in Mauritania and demonstrates the high genetic diversity of HBV in this country.
Journal of Medical Virology 08/2012; 84(8):1186-98. · 2.82 Impact Factor
-
Pascal Veillon,
Yves Gallois,
Valérie Moal,
Isabelle Fouchard-Hubert,
Isabelle Charles,
Françoise Larcher,
Nina Dib,
Jérôme Boursier,
Frédéric Oberti,
Jihane Laafi,
Jérôme Guéchot,
Viorica Balan,
Paul Calès, Françoise Lunel-Fabiani
[show abstract]
[hide abstract]
ABSTRACT: We compared three hyaluronic acid (HA) assays and analyzed the impact of their variations on FibroMeter scores.
In a test group of 165 patients, HA levels were assessed with the commonly used ELISA assay from Corgenix, a new ELISA assay from Teco and an immunoturbidimetry assay from Wako, this latter tested across three different instruments. Five different FibroMeter scores were calculated.
Correlation across the three assays (r(s) between 0.969 and 0.995) was very good. Means of differences (d) were lower when the immunoturbidimetry assay was compared on different instruments: d between -3.4 and 2.0 μg/L. However, a higher value for HA measurement was observed with Corgenix assay, compared to the other two assays (Teco and Wako): d between 27.1 and 36.4 μg/L. The assessment also demonstrated that HA variations had very little impact on FibroMeter scores: 0.0117 for virus and 0.0416 for alcoholic fibrosis scores, and between 0.58 and 1.71 for the area of fibrosis (expressed in percentage).
The two new assays found lower values of HA, as compared to the Corgenix assay. However, these differences had very little impact on FibroMeter scores and had no impact on clinical evaluation of liver fibrosis.
Clinica chimica acta; international journal of clinical chemistry 11/2010; 412(3-4):347-52. · 2.54 Impact Factor
-
Françoise Lunel-Fabiani,
Xavier Duburcq,
Thierry Levayer,
Frederique Descamps,
Michele Maniez-Montreuil,
Adeline Pivert,
Alexandra Ducancelle,
Agnes Pouzet,
Lydie Marant,
Anne Clèment,
David Duhamel,
Yannick Leirens,
Fanny Margotteau,
Roselyne Falcou-Briatte,
Christine Heinen,
Fabrice Bouniort,
Suhas Taskar,
Alain Artus,
David Woodrum,
Odile Flecheux
[show abstract]
[hide abstract]
ABSTRACT: Accurate detection of Hepatitis B Surface Antigen (HBsAg) is an important aid in the diagnosis of patients infected with the hepatitis B virus (HBV). A multi-center study was conducted to characterize the performance of the HBsAg assay on the family of Access immunoassay systems from Beckman Coulter.
The Access HBsAg assay was characterized in a multi-center study and compared to the Abbott AxSYM* and PRISM* HBsAg assays. The bioMérieux VIDAS* assay was used to resolve discrepant results. Reproducibility studies (intra-assay, inter-assay and inter-lot) were performed with pooled serum samples (negative sample, close to cut off, low, medium and high positive samples). Analytical sensitivity, subtype and genotype detection were studied with various commercial panels (SFTS panel, WHO 80/549, WHO 00/588, Teragenix HBV Genotype panel). A panel of recombinant HBsAg mutant proteins was tested to investigate reactivity towards genetic mutations. Clinical sensitivity was verified with seroconversion panels and samples from subjects with known HBV infection. Analytical specificity was studied with samples from patients with potential cross-reactive infections. Clinical specificity was validated among blood donors and a hospitalized population.
The imprecision was < 10%. Analytical sensitivity was < or = 0.1 ng/mL (SFTS panel), 0.020 PEI Units/mL (ad panel), 0.024 PEI Units/mL (ay panel), 0.092 IU/mL with WHO 80/549 and 0.056 IU/mL with WHO 00/588. All genotype samples and HBsAg mutants were reactive with the Access HBsAg assay. Seroconversion panels tested showed no significant difference with the reference method. Sensitivity for subjects with known HBV infection was 100%. No interference with potentially cross-reactive infections was observed after confirmatory testing. Specificity was 99.96% (100% after confirmatory testing) in a blood donor population and 99.5% (100% after confirmatory testing) in a hospitalized population. Excellent separation of positive and negative populations was observed.
The Access HBsAg and HBsAg Confirmatory assays meet all clinical and analytical performance requirements of assays for the detection of HBsAg.
Clinical laboratory 01/2010; 56(7-8):281-90. · 0.90 Impact Factor
-
Florence Legrand-Abravanel,
Philippe Colson,
Hélène Leguillou-Guillemette,
Laurent Alric,
Isabelle Ravaux, Françoise Lunel-Fabiani,
Magali Bouviers-Alias,
Pascale Trimoulet,
Marie Laure Chaix,
Christophe Hézode, [......],
Yazid Baazia,
Bruno Pozzetto,
Vincent Thibault,
Jean-Baptiste Nousbaum,
Dominique Roulot,
Henry Coppere,
Thierry Poynard,
Thierry Poinard,
Christopher Payan,
Jacques Izopet
[show abstract]
[hide abstract]
ABSTRACT: The hepatitis C virus genotype is considered to be the most important baseline predictor of a sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The influence of the subtype on the sustained virological response was investigated in patients infected with genotypes 1, 4, 5, or 6. This study was done on 597 patients with chronic hepatitis C who were given pegylated interferon and ribavirin for 48 weeks. The overall rate of sustained virological response in the 597 patients was 37.8%. Univariate analysis indicated that the sustained virological response of patients infected with subtype 1b (39%) tended to be higher than that of patients infected with subtype 1a (30.6%; P = 0.06) and it was similar to those patients infected with subtypes 4a (51.3%; P = 0.12) or 4d (51.7%; P = 0.16). Multivariate analysis indicated that five factors were independently associated with sustained virological response: the age (OR 0.97; 95% CI = 0.95-0.99), absence of cirrhosis (OR: 2.92; 95% CI = 1.7-5.0; P < 0.01), absence of HIV co-infection (OR: 2.08; 95% CI = 1.2-3.5; P < 0.01), low baseline plasma HCV RNA concentration (OR: 1.74; 95% CI = 1.2-2.6; P < 0.01), and the subtype 1b (OR: 1.61; 95% CI = 1.0-2.5; P = 0.04) or subtypes 4a and 4d (OR: 2.03; 95% CI = 1.1-3.8; P = 0.03). In conclusion, among difficult-to-treat genotypes, the subtype 1a is associated with a lower response to anti-HCV therapy than subtypes 1b, 4a, and 4d.
Journal of Medical Virology 12/2009; 81(12):2029-35. · 2.82 Impact Factor
-
Lionel Piroth,
Fabrice Carrat,
Sylvie Larrat,
Isabelle Goderel,
Benoit Martha,
Christopher Payan, Françoise Lunel-Fabiani,
Firouze Bani-Sadr,
Christian Perronne,
Patrice Cacoub,
Stanislas Pol,
Patrice Morand
[show abstract]
[hide abstract]
ABSTRACT: It has been suggested that, in HIV-HCV co-infected patients, co-infections with other viruses may affect the response to HCV therapy. We aimed to assess the prevalence of GBV-C, SEN-V and occult HBV infections, their impact on HCV and HIV infections and on the response to HCV therapy in HIV-HCV co-infected patients.
Three-hundred and sixty eight patients were tested before starting interferon-ribavirin for the presence of occult hepatitis B DNA, GBV-C RNA and SEN-V DNA by using real time PCR. Clinical, immunological, virological, histological characteristics and response to HCV therapy were compared according to the presence or not of each viral co-infection.
HBV DNA, GBV-C RNA and SEN-V DNA were found in 5 (1.4%, CI95%: 0.2-2.4%), 104 (29.9%, CI95%: 25.1-34.7%) and 209 patients (57.9%, CI95%: 52.8-63.0%), respectively. GBV-C positive patients had significantly higher CD4 count at baseline, during and after HCV therapy, even after stratification on antiretroviral treatment. No other significant difference was observed according to the presence or not of GBV-C or SEN-V co-infection, in particular regarding virological responses to HCV combination therapy.
There is no reason to withhold HCV therapy in HIV infected patients who have access to HAART, because of occult HBV, GBV-C or SEN-V co-infections.
Journal of Hepatology 08/2008; 49(6):892-8. · 9.26 Impact Factor
-
Firouzé Bani-Sadr,
Isabelle Goderel,
Nathanael Lapidus,
Henda Driss,
Anne Simon,
Eric Rosenthal,
Patrice Morand, Françoise Lunel-Fabiani,
Stanislas Pol,
Patrice Cacoub,
Christian Perronne,
Fabrice Carrat
AIDS (London, England) 08/2008; 22(11):1385-7. · 4.91 Impact Factor
-
Firouzé Bani-Sadr,
Isabelle Goderel,
Nathanael Lapidus,
Henda Driss,
Anne Simon,
Eric Rosenthal,
Patrice Morand, Françoise Lunel-Fabiani,
Stanislas Pol,
Patrice Cacoub,
Christian Perronne,
Fabrice Carrat,
and the ANRS - RIBAVIC Study team
AIDS 07/2008; 22(11):1385-1387. · 6.24 Impact Factor
-
Fabrice Carrat,
Pierre Bedossa, Françoise Lunel-Fabiani,
Patrice Morand,
Gilles Pialoux,
Lionel Piroth,
Dominique Salmon-Céron,
Firouzé Bani-Sadr,
Christian Perronne,
Patrice Cacoub,
Stanislas Pol
[show abstract]
[hide abstract]
ABSTRACT: We explored the link between serum alpha-fetoprotein levels and virologic response in 383 HIV-hepatitis C virus coinfected patients. A low alpha-fetoprotein level (<5.0 ng/ml) was an independent predictor of sustained virologic response (odds ratio = 1.83; 95% confidence interval 1.05-3.20). Serum alpha-fetoprotein measurement should be integrated in the pretreatment assessment of prognostic factors of a virologic response.
AIDS (London, England) 07/2008; 22(12):1513-5. · 4.91 Impact Factor
-
Paul Calès,
Pascal Veillon,
Anselme Konaté,
Elisabeth Mathieu,
Catherine Ternisien,
Alain Chevailler,
Alban Godon,
Yves Gallois,
Françoise Joubaud,
Isabelle Hubert-Fouchard,
Frédéric Oberti,
Stéphane Réaud,
Gilles Hunault,
Françoise Mauriat, Françoise Lunel-Fabiani
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the inter-laboratory reproducibility of blood test for liver fibrosis: FibroMeter, Fibrotest, APRI and their composites variables.
Four studies, including 147 patients, were performed: study #1 included 2 metachronous blood samples and 2 laboratories; studies #2, #3 and #4 included synchronous samples with assays delayed at day 1 in 12 laboratories, at day 0 in 10 laboratories and at day 0 or 1 in 2 laboratories, respectively. Agreement was evaluated by the intraclass correlation coefficient (r(ic)).
In studies #1, #2 and #4, r(ic) for FibroMeter was 0.893, 0.942 and 0.991, respectively. In study #3, the r(ic) were: FibroMeter: 0.963, Fibrotest: 0.984, APRI: 0.949. Large simulated variations in composite variables had a weak impact on FibroMeter.
When blood marker limits are controlled, inter-laboratory agreement of blood tests is excellent in clinical practice conditions. Blood tests are robust against the variability of composite blood variables.
Clinical Biochemistry 02/2008; 41(1-2):10-8. · 2.08 Impact Factor
-
JAIDS Journal of Acquired Immune Deficiency Syndromes 06/2007; 45(1):123-5. · 4.43 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: We conducted a national retrospective survey on hospital practitioners to evaluate the magnitude of erythropoietin (EPO) or granulocyte colony-stimulating factor (G-CSF) prescriptions in patients treated for chronic hepatitis C. Four hundred seventy-one questionnaires were sent, and 274 practitioners (58.2%) responded. Forty-six percent of practitioners used EPO, and 31% used G-CSF. The total number of HCV-infected patients receiving antiviral therapy per year was estimated at 6,630 patients, of whom 8.8% and 4% received EPO and G-CSF, respectively. EPO-beta was the main EPO molecule prescribed at a median dose of 30,000 IU/wk (range: 2,000-80,000). The indications for prescribing EPO varied greatly, including "fragile patients" (34%), "low" Hb level (8-11 g/dL) (19%), "rapid decline" in Hb level (2-5 g/dL during the first month of therapy) (12%), and symptomatic anemic patients (7%). G-CSF was mainly prescribed for a "low" level of neutrophils ranging from 400 to 750 neutrophils/mm3. In multivariate analysis, independent predictors of EPO and G-CSF prescription were age of practitioner less than 45 years (EPO: OR = 1.96, P = 0.03; G-CSF: OR = 2.27, P = 0.004), practice in university hospital (EPO: OR = 5.89, P < 0.0001; G-CSF: OR = 2.39, P = 0.003), and the high number of CHC treated/year (EPO: OR = 6.18, P < 0.0001; G-CSF: OR = 2.58, P = 0.002). Conclusion: Our survey reveals an important rate of EPO and G-CSF prescriptions but with considerable disparity in the schedule of injections, the molecules used, and above all the indications. The suitable role of EPO and G-CSF as complements to HCV therapy urgently needs to be clarified.
Hepatology 02/2007; 45(2):377-83. · 11.66 Impact Factor
-
Journal of Hepatology - J HEPATOL. 01/2007; 46.
-
[show abstract]
[hide abstract]
ABSTRACT: Pegylated interferon and ribavirin combination therapy represent the standard-of-care treatment for chronic hepatitis C, that allows to cure more than half of the patients. However, the success of this bitherapy is in balance with numerous side effects, especially hematologic and psychiatric. This review is focused on complementary treatments (erythropoietin, G-CSF, vitamin E, glutathion, ursodeoxycholic acid and antidepressants) likely to bring a benefit in maintaining adequate interferon and ribavirin dosages and in improving quality of life. This analysis has been performed by using the Medline(R) data base and with data from laboratories which commercialized these molecules. Erythropoietin, G-CSF and antidepressants are the best tools to optimize the bitherapy in its dose and its duration while privileging the quality of life of HCV-infected patients.
Gastroentérologie Clinique et Biologique 03/2006; 30(2):197-214. · 0.80 Impact Factor
-
Firouzé Bani-Sadr,
Fabrice Carrat,
Eric Rosenthal,
Lionel Piroth,
Patrice Morand, Françoise Lunel-Fabiani,
Mojgan Bonarek,
Nathalie Colin de Verdiere,
Gilles Pialoux,
Patrice Cacoub,
Stanislas Pol,
Christian Perronne
[show abstract]
[hide abstract]
ABSTRACT: Spontaneous hepatic decompensation was observed in 7 of 383 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving treatment with interferon and ribavirin. Multivariate analysis identified the following risk factors: didanosine use (odds ratio [OR], 8.8; 95% confidence interval [CI], 1.2-102.3; P < .02), cirrhosis, (OR, 8.8; 95% CI, 1.2-104.2; P<.02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly.
Clinical Infectious Diseases 12/2005; 41(12):1806-9. · 9.15 Impact Factor
-
Firouzé Bani-Sadr,
Fabrice Carrat,
Stanislas Pol,
Ravy Hor,
Eric Rosenthal,
Cécile Goujard,
Patrice Morand, Françoise Lunel-Fabiani,
Dominique Salmon-Ceron,
Lionel Piroth,
Gilles Pialoux,
Michèle Bentata,
Patrice Cacoub,
Christian Perronne
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy.
All cases of symptomatic mitochondrial toxicity reported in 416 patients participating in an open, randomized trial of peg-interferon alpha-2b plus ribavirin vs. interferon alpha-2b plus ribavirin for 48 weeks were reviewed. Associations with antiretroviral treatments and with clinical and laboratory findings were sought by univariate and multivariate analysis.
Eleven of the 383 patients who received at least 1 dose of anti-HCV treatment developed symptomatic mitochondrial toxicity (symptomatic hyperlactatemia and pancreatitis in 6 and 5 patients, respectively). All cases occurred in patients being treated for HIV infection, and the incidence of symptomatic mitochondrial toxicity was 47.5 per 1000 patient-years. In multivariate analysis, symptomatic mitochondrial toxicity was significantly associated with didanosine-containing antiretroviral regimens (odds ratio 46; 95% CI, 7.4 to infinity; P < 0.001), but not with stavudine or with nucleoside reverse transcriptase inhibitor regimens not containing didanosine. The incidence of symptomatic mitochondrial toxicity was 200.2 per 1000 patient-years in patients receiving didanosine. Demographic characteristics were not associated with symptomatic mitochondrial toxicity.
Coadministration of ribavirin with didanosine should be avoided. If unavoidable, patients should be monitored closely for mitochondrial toxicity. Didanosine should be suspended if clinical signs or symptoms of mitochondrial toxicity occur.
JAIDS Journal of Acquired Immune Deficiency Syndromes 09/2005; 40(1):47-52. · 4.43 Impact Factor
-
Fabrice Carrat,
Firouzé Bani-Sadr,
Stanislas Pol,
Eric Rosenthal, Françoise Lunel-Fabiani,
Asmae Benzekri,
Patrice Morand,
Cécile Goujard,
Gilles Pialoux,
Lionel Piroth,
Dominique Salmon-Céron,
Claude Degott,
Patrice Cacoub,
Christian Perronne
[show abstract]
[hide abstract]
ABSTRACT: Treatment of chronic hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients is a growing concern. Most data on the virologic efficacy and safety of the combination of peginterferon alfa-2b and ribavirin in coinfected patients come from uncontrolled studies.
To study the safety and efficacy of peginterferon alfa-2b plus ribavirin vs standard interferon alfa-2b plus ribavirin in HIV-HCV coinfected patients.
A multicenter, randomized, parallel-group, open-label trial. Patients were enrolled from February 2000 to February 2002 and followed up for 72 weeks.
Four hundred twelve HIV-HCV coinfected patients with detectable serum HCV-RNA, abnormal liver histology, a CD4 cell count of at least 200 x 10(6)/L, and stable plasma HIV-RNA.
Treatment with ribavirin 400 mg twice a day, orally, plus either peginterferon alfa-2b (1.5 microg/kg subcutaneous injection once a week) or standard interferon alfa-2b (3 million units of subcutaneous injection 3 times a week) for 48 weeks.
Sustained virologic response, defined by undetectable serum HCV-RNA at week 72.
More patients had sustained virologic responses in the peginterferon group than in the standard interferon group (27% vs 20%, P = .047). This difference between the treatments was found in patients with HCV genotype 1 or 4 infection (17% for peginterferon vs 6% for standard interferon, P = .006) but was not found in patients with HCV genotype 2, 3, or 5 (44% for peginterferon vs 43% for standard interferon, P = .88). Together, a decline in HCV-RNA of less than 2 log10 from baseline and detectable serum HCV-RNA at week 12 predicted 99% of treatment failures. Histologic activity diminished and fibrosis stabilized in virologic responders. The 2 regimens showed similar tolerability although dose modifications for clinical and biological events were more frequent with peginterferon. Eleven cases of pancreatitis or symptomatic hyperlactatemia were observed, all in patients receiving didanosine-containing antiretroviral regimens.
In combination with ribavirin, treatment with peginterferon alfa-2b is more effective than standard interferon alfa-2b for HCV infection in HIV-infected patients.
JAMA The Journal of the American Medical Association 01/2005; 292(23):2839-48. · 30.03 Impact Factor
-
Thomas Bourlet,
Rachel Levy,
Silvy Laporte,
Stéphane Blachier,
Laurence Bocket,
Guy Cassuto,
Lionel Chollet,
Marianne Leruez-Ville,
Anne Maertens,
Fabienne Mousnier, [......],
Gilles Duverlie,
Jacques Izopet, Françoise Lunel-Fabiani,
Jean-Michel Pawlotsky,
Nerina Profizi,
Christine Rouzioux,
Françoise Stoll-Keller,
Vincent Thibault,
Pierre Wattré,
Bruno Pozzetto
[show abstract]
[hide abstract]
ABSTRACT: The discrepant results available in the literature about the presence of hepatitis C virus (HCV) RNA in seminal plasma of men chronically infected by this agent are related, at least in part, to the molecular techniques used and particularly to the wide range of protocols dedicated to RNA extraction. In order to evaluate these protocols and to standardize the method of detection of HCV RNA in this fluid, a panel of coded specimens was tested blindly in 12 French laboratories; it included 14 seminal plasma specimens and four water controls spiked with HCV RNA ranging from 10 to 20000 IU/ml and two HCV-negative seminal plasma specimens. The extraction step was performed according to methods using either silica beads (NucliSens [Organon Teknika S.A., Fresnes, France]; RNA viral kit [Qiagen, Courtaboeuf, France]) or guanidinium thiocyanate (Amplicor HCV assay; Roche Diagnostics, Meylan, France), preceded or not by a centrifugation of the seminal plasma. For the amplification step, all the laboratories performed the same reverse transcription-PCR technique (Amplicor HCV Cobas assay). The percentage of correct results ranged from 53.3 to 100, the poorest results being obtained when no centrifugation step preceded the Amplicor extraction protocol. The rate of correct results was significantly higher in laboratories using a preliminary centrifugation of the specimen (P = 0.034 by chi-square test). By contrast, the overall number of correct results was not correlated to the initial volume of sample used for the test. These results allowed us to validate standardized techniques adapted to the performance of this test on a routine basis, especially in men infected with HCV and involved in programs of medically assisted reproduction.
Journal of Clinical Microbiology 03/2003; 41(2):789-93. · 4.15 Impact Factor
-
Hepatology 06/2002; 35(5):1281-2. · 11.66 Impact Factor
-
Gastroentérologie Clinique et Biologique 27(8-9):718-26. · 0.80 Impact Factor
